Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. (18th November 2021)

• Record Type: Journal Article
• Authors: Collier, Ai-ris Y; Yu, Jingyou; McMahan, Katherine; Liu, Jinyan; Atyeo, Caroline; Ansel, Jessica L; Fricker, Zachary P; Pavlakis, Martha; Curry, Michael P; Jacob-Dolan, Catherine; Patel, Het; Sellers, Daniel; Barrett, Julia; Rowe, Marjorie; Ahmad, Kunza; Gompers, Annika; Aguayo, Ricardo; Chandrashekar, Abishek; Alter, Galit; Hacker, Michele R; Barouch, Dan H
• Is Part Of: Journal of infectious diseases. Volume 225:Number 7(2022)
• Page Start: 1124
• Page End: 1128
• Publication Date: 2021-11-18
• Subjects: immunocompromised -- COVID -- 19 vaccine -- SARS -- CoV -- 2 -- vaccine immunogenicity -- T cells; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiab569
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Individuals on immunosuppressive (IS) therapy have increased mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and delayed viral clearance may lead to new viral variants. IS therapy reduces antibody responses following coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccination; however, a comprehensive assessment of vaccine immunogenicity is lacking. Here we show that IS therapy reduced neutralizing, binding, and nonneutralizing antibody functions in addition to CD4 and CD8 T-cell interferon-γ responses following COVID-19 mRNA vaccination compared to immunocompetent individuals. Moreover, IS therapy reduced cross-reactivity against SARS-CoV-2 variants. These data suggest that the standard COVID-19 mRNA vaccine regimens will likely not provide optimal protection in immunocompromised individuals. Abstract : Individuals on immunosuppression for various indications have impaired neutralizing, binding, and nonneutralizing antibody responses and reduced T-cell activity in response to COVID-19 mRNA vaccination compared to immunocompetent controls. This suggests that standard vaccination may not result in protective immunity in this population.